AstraZeneca NSCLC Webinar
AstraZeneca invites you to join us for a webinar on “Challenges in Treating Patients with Unresectable Stage III NSCLC.” This session will explore the latest advancements and strategies in managing non-small cell lung cancer, particularly in patients who are not candidates for surgery. Experts will discuss treatment options, patient care considerations, and emerging therapies. Ideal for healthcare professionals, this webinar offers valuable insights and practical guidance for improving patient outcomes in this complex area of oncology.
Planning and coordinating the event’s agenda, securing expert speakers, managing the technical aspects of the webinar platform. Promotional activities, creating marketing materials and outreach to target audiences. Management of participant registration, providing technical support during the event, ensuring smooth execution. Post-event tasks include collecting feedback, distributing recorded sessions, and analyzing engagement metrics.
Improving health is one of the greatest challenges the world faces today.
As a global innovative biopharmaceutical company, AstraZeneca plays a crucial role in discovering, developing, and distributing innovative medicines in key areas of healthcare, including cardiovascular, renal, and metabolic diseases, respiratory diseases, inflammatory and autoimmune disorders, and oncology. The company was established in 1999 through the merger of Sweden’s Astra AB and the UK’s Zeneca Group, becoming one of the largest pharmaceutical companies in the world. It has since made numerous corporate acquisitions, including Cambridge Antibody Technology (2006), MedImmune (2007), Spirogen (2013), and Definiens (MedImmune 2014).
In Serbia, AstraZeneca focuses on the following therapeutic areas: cardiovascular, renal, and metabolic diseases, oncology, and respiratory diseases and immunology.
